Literature DB >> 11771738

Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome.

E Engidawork1, J F Juranville, M Fountoulakis, M Dierssen, G Lubec.   

Abstract

The ubiquitin-proteasome proteolytic pathway is involved in an important non-lysosomal proteolytic pathway that is responsible for the highly selective turnover of cellular proteins both under basal metabolic conditions as well as stress. Protein degradation by this pathway is attributed to the 20S proteasome that forms the catalytic core of the complex. Recently there has been increasing interest in the proteasome because of its possible role in neuron degeneration and death. Fetal Down syndrome (DS) neurons were demonstrated to degenerate and undergo apoptosis in vitro. We therefore investigated the expression of different proteins involved in this degradative pathway, including subunits of the 20S proteasome, ubiquitinating and deubiquitinating enzymes, and regulatory subunits of the 26S proteasome in control and DS fetal brains by two-dimensional electrophoresis (2-DE). After 2-DE, approximately 389 protein spots were successfully identified by matrix-associated laser desorption ionization mass spectroscopy (MALDI-MS) and this was followed by quantification of twenty three proteins of the pathway. The results indicate that all but two proteins exhibited no apparent alterations in their pattern of expression. Proteasome zeta chain, an alpha subunit of the 20S proteasome (P < 0.05) and ubiquitin carboxy-terminal hydrolase T (Isopeptidase T), a deubiquitinating enzyme (P < 0.001) were significantly increased in fetal DS compared to controls. Whilst the expression of proteasome iota (n = 9, r = -0.9489, P = 0.0004) and proteasome epsilon (n = 9, r = -0.7227, P = 0.0311) chains was decreased with age in fetal DS brain, no significant correlation was obtained in the other proteins with age. The data suggest that such selective upregulation may have relevance to the developmental abnormalities that characterize this disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771738     DOI: 10.1007/978-3-7091-6262-0_10

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  6 in total

1.  Global hypermethylation in fetal cortex of Down syndrome due to DNMT3L overexpression.

Authors:  Jie Lu; Monika Mccarter; Gewei Lian; Giuseppe Esposito; Elena Capoccia; Laurent C Delli-Bovi; Jonathan Hecht; Volney Sheen
Journal:  Hum Mol Genet       Date:  2016-02-23       Impact factor: 6.150

Review 2.  Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics.

Authors:  Marzia Perluigi; Fabio Di Domenico; D Allan Buttterfield
Journal:  Proteomics Clin Appl       Date:  2014-02       Impact factor: 3.494

3.  Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

Authors:  M Nistor; M Don; M Parekh; F Sarsoza; M Goodus; G E Lopez; C Kawas; J Leverenz; E Doran; I T Lott; M Hill; E Head
Journal:  Neurobiol Aging       Date:  2006-08-09       Impact factor: 4.673

4.  Analysis of plausible downstream target genes of Hoxc8 in F9 teratocarcinoma cells. Putative downstream target genes of Hoxc8.

Authors:  Yunjeong Kwon; Jeong Heon Ko; Kim Byung-Gyu; Myoung Hee Kim; Byungkyu Kim
Journal:  Mol Biol Rep       Date:  2003-09       Impact factor: 2.316

5.  Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome.

Authors:  Zhihou Liang; Fei Liu; Khalid Iqbal; Inge Grundke-Iqbal; Jerzy Wegiel; Cheng-Xin Gong
Journal:  J Alzheimers Dis       Date:  2008-04       Impact factor: 4.472

6.  Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome.

Authors:  Barbara Granese; Iris Scala; Carmen Spatuzza; Anna Valentino; Marcella Coletta; Rosa Anna Vacca; Pasquale De Luca; Generoso Andria
Journal:  BMC Med Genomics       Date:  2013-07-05       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.